Rosa Montesinos
Overview
Explore the profile of Rosa Montesinos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandey N, Yang Z, Cieza B, Reyes-Dumeyer D, Kang M, Montesinos R, et al.
Alzheimers Res Ther
. 2025 Jan;
17(1):1.
PMID: 39743558
Background: Blood-based Alzheimer's disease (AD) biomarkers have been increasingly employed for diagnostic, prognostic, and therapeutic monitoring purposes, due to accuracy in distinguishing AD pathophysiologic process. Compared to other p-tau isoforms,...
2.
Malaga M, Aguirre R, Alva-Diaz C, Custodio N, Lanata S, Montesinos R, et al.
Arq Neuropsiquiatr
. 2024 Sep;
82(9):1-9.
PMID: 39341209
Background: Primary care physicians and other healthcare providers report feeling unprepared to treat persons with dementia (PWD), especially in developing countries OBJECTIVE: We aimed to assess the knowledge of dementia...
3.
Montesinos R, Custodio B, Malaga M, Chambergo-Michilot D, Verastegui-Aranda G, Aguero K, et al.
Dement Geriatr Cogn Disord
. 2024 May;
53(5):229-236.
PMID: 38768581
Introduction: People caring for patients with dementia are prone to suffering from burden. Behavioral and psychological symptoms of dementia (BPSD) may have an impact on caregiver burden. In Latin American...
4.
Yang Z, Cieza B, Reyes-Dumeyer D, Montesinos R, Soto-Anari M, Custodio N, et al.
Brief Bioinform
. 2023 Dec;
25(1).
PMID: 38037235
Objective: The performances of popular genome-wide association study (GWAS) models have not been examined yet in a consistent manner under the scenario of genetic admixture, which introduces several challenging aspects:...
5.
Herrera-Perez E, Custodio N, Diaz M, Montesinos R, Chang A, Villafuerte M, et al.
Front Public Health
. 2023 Nov;
11:1228008.
PMID: 37927880
Background: In Latin America (LA), the prevalence of dementia is expected to triple to 150 million people by 2050. The 2020 Lancet Commission report identified several modifiable dementia risk factors,...
6.
Custodio N, Malaga M, Montesinos R, Chambergo-Michilot D, Baca F, Carbajal J, et al.
Dement Geriatr Cogn Disord
. 2023 Oct;
52(5-6):309-317.
PMID: 37827146
Introduction: As disease-modifying therapies become available for Alzheimer's disease (AD), detection of AD in early stages of illness (mild cognitive impairment [MCI], early dementia) becomes increasingly important. Biomarkers for AD...
7.
Crivelli L, Calandri I, Suemoto C, Salinas R, Velilla L, Yassuda M, et al.
Alzheimers Dement
. 2023 May;
19(9):4046-4060.
PMID: 37204054
Introduction: Latin American Initiative for Lifestyle Intervention to Prevent Cognitive Decline (LatAm-FINGERS) is the first non-pharmacological multicenter randomized clinical trial (RCT) to prevent cognitive impairment in Latin America (LA). Our...
8.
Yang Z, Huaman B, Reyes-Dumeyer D, Montesinos R, Soto-Anari M, Custodio N, et al.
bioRxiv
. 2023 May;
PMID: 37163101
Objective: The performances of popular Genome-wide association study (GWAS) models haven't been examined yet in a consistent manner under the scenario of genetic admixture, which introduces several challenging aspects such...
9.
Custodio N, Malaga M, Montesinos R, Chambergo D, Baca F, Castro S, et al.
Curr Alzheimer Res
. 2023 Apr;
20(2):80-88.
PMID: 37073648
Background: Neuropsychiatric symptoms (NPS) in patients with Alzheimer's disease (AD) worsened during the COVID-19 lockdowns, but their progression thereafter is unknown. We present the first longitudinal study tracking them before,...
10.
Custodio N, Malaga M, Chambergo-Michilot D, Montesinos R, Moron E, Vences M, et al.
Front Neurol
. 2022 Sep;
13:962192.
PMID: 36119675
Background: Many low- and middle-income countries, including Latin America, lack access to biomarkers for the diagnosis of prodromal Alzheimer's Disease (AD; mild cognitive impairment due to AD) and AD dementia....